Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Mezagitamab (TAK-079), an IgG1λ anti-CD38 monoclonal antibody, functions by depleting tumor cells that express CD38 through both antibody and complement-dependent cytotoxicity. It shows potential for use in the treatment of relapsed/refractory multiple myeloma (RRMM) and idiopathic thrombocytopenic purpura (ITP) [1] [2] [3].
説明 | Mezagitamab (TAK-079), an IgG1λ anti-CD38 monoclonal antibody, functions by depleting tumor cells that express CD38 through both antibody and complement-dependent cytotoxicity. It shows potential for use in the treatment of relapsed/refractory multiple myeloma (RRMM) and idiopathic thrombocytopenic purpura (ITP) [1] [2] [3]. |
分子量 | N/A |
CAS No. | 2227490-52-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Mezagitamab 2227490-52-8 Inhibitor inhibitor inhibit